Title: Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20150301
Title: Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.
Journal: The Journal of biological chemistry 20120622
Title: Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Journal: The Journal of pharmacology and experimental therapeutics 20110901
Title: Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
Journal: Cancer chemotherapy and pharmacology 20100501
Title: Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Journal: BMC cancer 20100101
Title: Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Journal: Anti-cancer drugs 20090601
Title: Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.
Journal: Journal of translational medicine 20090101
Title: Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
Journal: Biochemical and biophysical research communications 20080321
Title: Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.
Journal: Journal of the National Cancer Institute 20060802
Title: CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome.
Journal: Anticancer research 20060101
Title: EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828.
Journal: Bioorganic & medicinal chemistry letters 20050516
Title: Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050501
Title: Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
Journal: European journal of cancer (Oxford, England : 1990) 20050301
Title: Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice.
Journal: Neuroendocrinology 20050101
Title: Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity.
Journal: International journal of cancer 20040820
Title: Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828.
Journal: Molecular cancer therapeutics 20040501
Title: Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives.
Journal: Bioorganic & medicinal chemistry letters 20040308
Title: Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.
Journal: Anti-cancer drugs 20040101
Title: Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.
Journal: Anti-cancer drugs 20040101
Title: Segmental analysis of molecular surface electrostatic potentials: application to enzyme inhibition.
Journal: Journal of molecular modeling 20030401
Title: Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828.
Journal: Drugs under experimental and clinical research 20030101
Title: The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.
Journal: British journal of pharmacology 20021001
Title: Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Journal: Chemotherapy 20020901
Title: A Phase I study of CHS 828 in patients with solid tumor malignancy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020901
Title: Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1.
Journal: Cancer research 20020801
Title: In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia.
Journal: Anti-cancer drugs 20020801
Title: CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
Journal: Pediatric research 20020501
Title: Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.
Journal: Biochemical pharmacology 20020415
Title: Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells.
Journal: Anticancer research 20020101
Title: Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
Journal: The Journal of pharmacology and experimental therapeutics 20011201
Title: Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro.
Journal: Anti-cancer drugs 20011101
Title: Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
Journal: Biochemical pharmacology 20010515
Title: Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone).
Journal: European journal of pharmacology 20010420
Title: Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells.
Journal: European journal of pharmacology 20010413
Title: In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.
Journal: Cancer letters 20010126
Title: Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells.
Journal: European journal of cancer (Oxford, England : 1990) 20010101
Title: A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828.
Journal: Anti-cancer drugs 20010101
Title: Rapid screening of Veillonella by ultraviolet fluorescence.
Journal: Journal of clinical microbiology 19751201
Title: Watson M, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol. 2009 Nov;29(21):5872-88.
Title: Cerna D, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J Biol Chem. 2012 Jun 22;287(26):22408-17.
